275 related articles for article (PubMed ID: 8380343)
1. CIS-19, a novel platelet activating factor receptor antagonist: in vitro and in vivo studies.
Ko FN; Yu SM; Chen IS; Ishii H; Chang YL; Huang TF; Teng CM
Biochim Biophys Acta; 1993 Jan; 1175(2):225-31. PubMed ID: 8380343
[TBL] [Abstract][Full Text] [Related]
2. PAF antagonism in vitro and in vivo by aglafoline from Aglaia elliptifolia Merr.
Ko FN; Wu TS; Liou MJ; Huang TF; Teng CM
Eur J Pharmacol; 1992 Jul; 218(1):129-35. PubMed ID: 1327822
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of collagen-induced platelet aggregation and adhesion by a pseudocyanide derivative of avicine isolated from Zanthoxylum integrifoliolum Merr.
Ko FN; Hsiao G; Chen IS; Wu SJ; Teng CM
Biochem Pharmacol; 1993 Oct; 46(7):1165-73. PubMed ID: 8216367
[TBL] [Abstract][Full Text] [Related]
4. Platelet-activating factor (PAF) inhibitory profile of KO-286011 on blood platelets in vitro and in vivo.
Ostermann G; Hofmann B; Kertscher HP; Till U
Naunyn Schmiedebergs Arch Pharmacol; 1990 Dec; 342(6):713-8. PubMed ID: 2096302
[TBL] [Abstract][Full Text] [Related]
5. Comparison of three paf-acether receptor antagonist ginkgolides.
Korth R; Nunez D; Bidault J; Benveniste J
Eur J Pharmacol; 1988 Jul; 152(1-2):101-10. PubMed ID: 2850196
[TBL] [Abstract][Full Text] [Related]
6. Biological effects of the new platelet-activating factor receptor antagonist (+)-cis-3,5-dimethyl-2-(3-pyridyl)thiazolidin-4-one hydrochloride.
Imanishi N; Murakami-Uchida M; Koike H; Natsume Y; Morooka S
Arzneimittelforschung; 1994 Mar; 44(3):317-22. PubMed ID: 8192697
[TBL] [Abstract][Full Text] [Related]
7. Bakkenolide G, a natural PAF-receptor antagonist.
Liao CH; Ko FN; Wu TS; Teng CM
J Pharm Pharmacol; 1997 Dec; 49(12):1248-53. PubMed ID: 9466352
[TBL] [Abstract][Full Text] [Related]
8. The effect of the selective PAF antagonist CIS-19 on PAF- and antigen-induced bronchoconstriction, microvascular leakage and bronchial hyperreactivity in guinea-pigs.
Lin CH; Ko FN; Ishii H; Ishikawa T; Chen IS; Teng CM; Kuo HP
Naunyn Schmiedebergs Arch Pharmacol; 1997 Feb; 355(2):210-6. PubMed ID: 9050014
[TBL] [Abstract][Full Text] [Related]
9. Specific inhibition of PAF-acether-induced platelet activation by BN 52021 and comparison with the PAF-acether inhibitors kadsurenone and CV 3988.
Nunez D; Chignard M; Korth R; Le Couedic JP; Norel X; Spinnewyn B; Braquet P; Benveniste J
Eur J Pharmacol; 1986 Apr; 123(2):197-205. PubMed ID: 3086108
[TBL] [Abstract][Full Text] [Related]
10. Biochemical and pharmacological activities of SR 27417, a highly potent, long-acting platelet-activating factor receptor antagonist.
Herbert JM; Bernat A; Valette G; Gigo V; Lale A; LaPlace MC; Lespy L; Savi P; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1991 Oct; 259(1):44-51. PubMed ID: 1656029
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of thrombin- and collagen-induced phosphoinositides breakdown in rabbit platelets by a PAF antagonist--denudatin B, an isomer of kadsurenone.
Teng CM; Yu SM; Chen CC; Huang YL; Huang TF
Thromb Res; 1990 Jul; 59(1):121-30. PubMed ID: 2169076
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet action of 3',4'-diisovalerylkhellactone diester purified from Peucedanum japonicum Thunb.
Hsiao G; Ko FN; Jong TT; Teng CM
Biol Pharm Bull; 1998 Jul; 21(7):688-92. PubMed ID: 9703250
[TBL] [Abstract][Full Text] [Related]
13. Pharmacological characterization of cinnamophilin, a novel dual inhibitor of thromboxane synthase and thromboxane A2 receptor.
Yu SM; Wu TS; Teng CM
Br J Pharmacol; 1994 Mar; 111(3):906-12. PubMed ID: 8019768
[TBL] [Abstract][Full Text] [Related]
14. HA-29: an inhibitor of thromboxane A2 formation with antagonism of thromboxane A2/prostaglandin endoperoxide receptor in rabbit platelets.
Lin CH; Kuo SC; Huang LJ; Huang TF; Teng CM
Thromb Res; 1992 Apr; 66(1):61-73. PubMed ID: 1412184
[TBL] [Abstract][Full Text] [Related]
15. Changes in cytosolic free calcium induced by platelet-activating factor in rabbit platelets: specific inhibition by BN 52021 and structurally related compounds.
Baroggi N; Etienne A; Braquet P
Agents Actions Suppl; 1986; 20():87-97. PubMed ID: 3028108
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological properties of YM461, a new orally active platelet-activating factor antagonist.
Yamada T; Saito M; Mase T; Hara H; Nagaoka H; Murase K; Tomioka K
Lipids; 1991 Dec; 26(12):1179-83. PubMed ID: 1668114
[TBL] [Abstract][Full Text] [Related]
17. Triflavin potentiates the antiplatelet activity of platelet activating factor receptor antagonist on activated neutrophil-induced platelet aggregation.
Lee LW; Peng HC; Ko WC; Hung WC; Su CH; Lin CH; Huang TF; Yen MH; Sheu JR
Eur J Pharmacol; 1999 Jan; 364(2-3):239-46. PubMed ID: 9932729
[TBL] [Abstract][Full Text] [Related]
18. Action of platelet-activating factor (PAF) antagonists on the bronchopulmonary effects of PAF in the guinea-pig.
Pons F; Touvay C; Lejeune V; Carré C; Vilain B; Broquet C; Mencia-Huerta JM; Braquet P
J Lipid Mediat; 1989; 1(6):329-40. PubMed ID: 2519901
[TBL] [Abstract][Full Text] [Related]
19. 1,4-Dihydropyridines, a new class of platelet-activating factor receptor antagonists: in vitro pharmacologic studies.
Ortega MP; García MC; Gijón MA; de Casa-Juana MF; Priego JG; Sanchez Crespo M; Sunkel C
J Pharmacol Exp Ther; 1990 Oct; 255(1):28-33. PubMed ID: 2170624
[TBL] [Abstract][Full Text] [Related]
20. Rupatadine, a new potent, orally active dual antagonist of histamine and platelet-activating factor (PAF).
Merlos M; Giral M; Balsa D; Ferrando R; Queralt M; Puigdemont A; García-Rafanell J; Forn J
J Pharmacol Exp Ther; 1997 Jan; 280(1):114-21. PubMed ID: 8996188
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
